<PAGE>

                                  UNITED STATES

                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                  FORM 10-QSB/A

                                   (Mark One)

        |X| QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES

                              EXCHANGE ACT OF 1934

                For the quarterly period ended December 31, 2003

       |_| TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE EXCHANGE ACT

                        For the transition period from to

                        Commission file number 000-24001

                               IQ BIOMETRIX, INC.


        (Exact name of small business issuer as specified in its charter)



              Delaware                                      76-0552098
---------------------------------------------           -------------------
(State or other jurisdiction of incorporation             (IRS Employer
   or organization)                                     Identification No.)


         39111 Paseo Padre Parkway, Suite 304, Fremont, California 94538
                    (Address of principal executive offices)

                                 (510) 795-2900
                          (Issuer's telephone number)

State the number of shares outstanding of each of the issuer's classes of common
equity, as of the latest practicable date: As of January, 31, 2004 the
registrant had 22,778,142 shares of its common stock outstanding.

Check whether the issuer (1) filed all reports required to be filed by Section
13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. Yes[X] No [ ]

Transitional Small Business Disclosure Format (Check one): Yes [ ] No [X]



<PAGE>


                                TABLE OF CONTENTS

                               FORM 10-QSB REPORT

                                December 31, 2003



                                                                           PAGE
PART I - FINANCIAL INFORMATION
   Item  1.  Interim  condensed  financial  statements (unaudited)          3
     Consolidated Balance Sheet  December 31, 2003                          3
     Consolidated  Statement of Operations for the three and six months
       ended December 31, 2002 and 2003                                     4
     Consolidated Statement of Cash Flows for the six
        months ended December 31, 2002 and 2003                             5
     Notes to Interim Financial Statements                                  6

   Item 2. Management's Discussion and Analysis or Plan of Operation        6

PART II - OTHER INFORMATION
   Item 2. Changes in Securities and Use of Proceeds                       19
   Item 3. Controls and Procedures                                         19
   Item 6. Exhibits and Reports on Form 8-K                                20

SIGNATURES

                                        2

<PAGE>
                          PART I. FINANCIAL STATEMENTS

ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

                           CONSOLIDATED BALANCE SHEET
                                December 31, 2003


<TABLE>
<CAPTION>

                               ASSETS
<S>                                                                                               <C>
CURRENT ASSETS:
Cash                                                                                              $     374,405
Trade accounts receivable, net of allowance for doubtful accounts of $  0                                45,635
Inventory                                                                                                11,188
Other                                                                                                    19,074
                                                                                                  -------------
                               Total current assets                                                     450,302
INTANGIBLES, net                                                                                        126,126
OFFICE EQUIPMENT, net                                                                                     7,562
                                                                                                  -------------
                               Total assets                                                       $     583,990
                                                                                                  =============
                               LIABILITIES AND STOCKHOLDERS' DEFICIT
CURRENT LIABILITIES:
Convertible debentures, net of discount                                                           $   1,208,442
Accounts payable                                                                                         44,270
Accrued expenses                                                                                        107,505
                                                                                                  -------------
                               Total current liabilities                                              1,360,207
COMMITMENTS

STOCKHOLDERS' DEFICIT:
Preferred stock, $.01 par value; 10,000,000 shares authorized, none issued -
Common stock, $.01 par value; 50,000,000 shares authorized, 22,778,142 shares
outstanding, $227,782; additional paid-in capital $7,174,376; Accumulated
deficit ($8,178,385)

                               Total stockholders' deficit                                             (776,227)
                                                                                                  -------------
                               Total liabilities and stockholders' deficit                        $     583,990
                                                                                                  =============
</TABLE>

The accompanying notes are an integral part of these consolidated financial
statements.

                                        3

<PAGE>


                               IQ BIOMETRIX, INC.
                            STATEMENTS OF OPERATIONS
                                   (Unaudited)


<TABLE>
<CAPTION>

                                                  For the three months ended             For the six months ended
                                                         December 31,                          December 31,
                                                    2003                2002              2003              2002
                                              ---------------     ---------------   ----------------  ----------------
<S>                                           <C>                        <C>               <C>                <C>
Revenues                                      $      55,253              28,305            138,348            49,387
Operating expenses

   Cost of sales                                     36,014              13,237             51,082            27,592
   Sales and marketing                               32,120              37,056            180,814            85,884
   General and administrative                       868,684             328,869          2,300,514           611,162
   Research and development                          61,200              55,028            150,168            80,267
   Impairment                                        20,042              52,401             20,042            52,401
   Depreciation                                       1,053                   0              7,668                 0
                                              ---------------     ---------------   ----------------  ----------------
                                                  1,019,113             486,591          2,710,288           857,306
                                              ---------------     ---------------   ----------------  ----------------
     Operating loss                                (963,860)           (458,286)        (2,571,940)         (807,919)
Other Expense:
   Interest Expense, net                            408,381               9,112            734,489            19,112
                                              ---------------     ---------------   ----------------  ----------------
Net Loss                                      $  (1,372,241)           (467,398)        (3,306,429)         (827,031)
                                              ===============     ===============   ================  ================

Basic and Diluted loss per share                     ($0.06)             ($0.03)            ($0.16)           ($0.05)
Weighted average shares
   outstanding                                   21,172,208          16,517,785         20,193,034        16,502,785
</TABLE>

The accompanying notes are an integral part of these consolidated financial
statements.

                                        4
<PAGE>


                                IQ BIOMETRIX, INC
                             STATEMENT OF CASH FLOWS
                                   (Unaudited)

<TABLE>
<CAPTION>


                                                                    For the Six Months Ended
                                                                          December 31,
                                                                      2003               2002
                                                                ---------------     ---------------
<S>                                                             <C>                 <C>
OPERATING ACTIVITIES:
   Net loss                                                     $   (3,306,429)     $     (827,031)
   Adjustments to reconcile net loss to
        net cash used in operating activities
          Depreciation and amortization                                 37,123              13,470
          Stock Warrants issued as interest on loans                        --              19,112
          Common stock issued for services                           2,382,431              64,517
          Common stock issued for debt                                 190,962                  --
          Impairment                                                    20,042              52,401
          Amortization of debt discount                                595,935                  --
             Changes in assets and liabilities:
               Account receivable                                      (39,662)                 --
               Advance to IQ Entertainment                                  --             (26,121)
               Inventory                                                (5,180)             12,000
               Prepaid expenses                                         18,808                  --
               Accounts payable and accrued expenses                  (197,161)             92,426
                                                                ---------------     ---------------
   Net cash used in operating activities                              (303,181)           (599,226)
                                                                ---------------     ---------------

     Investing activities
               Purchase of fixed assets                                 (1,845)                 --
               Purchase of Intellectual Property                       (50,000)                 --
               Collection of note receivable                            50,000                  --
                                                                ---------------     ---------------
   Net cash used in investing activities                                (1,845)                 --
                                                                ---------------     ---------------
   Financing activities

               Proceeds from sale of common stock                           --             200,000
               Proceeds from exercise of warrants                       31,700                  --
               Proceeds from new convertible notes payable             600,000             350,000
               Proceeds from demand notes payable                      (50,000)             50,000
                                                                ---------------     ---------------
   Net cash provided by financing activities                           581,700             600,000
                                                                ---------------     ---------------
   Net increase (decrease) in cash                                     276,724                 774

   Cash, beginning of year                                              97,681              92,213
                                                                ---------------     ---------------
   Cash, end of year                                            $      374,405      $       92,987
                                                                ===============     ===============
   Supplemental cash flow information
    Non-cash investing and financing activities
          Interest expense not paid
          Taxes paid

</TABLE>


The accompanying notes are an integral part of these consolidated financial
statements.

                                        5
<PAGE>
                               IQ BIOMETRIX, INC.

                      NOTES TO INTERIM FINANCIAL STATEMENTS
                                   (Unaudited)

NOTE 1 - BASIS OF PRESENTATION

The accompanying unaudited interim financial statements of IQ Biometrix, Inc.
have been prepared in accordance with accounting principles generally accepted
in the United States of America, the rules of the Securities and Exchange
Commission ("SEC") and with the instructions to Form 10-QSB, and should be read
in conjunction with the audited financial statements and notes thereto contained
in IQ Biometrix's 2003 Annual Report on Form 10-KSB filed with the SEC on
October 14, 2003 as amended on February 6, 2004. In the opinion of management,
all adjustments, consisting of normal recurring adjustments, necessary for a
fair presentation of financial position and the results of operations for the
interim periods presented have been reflected herein. The results of operations
for interim periods are not necessarily indicative of the results to be expected
for the full year. Notes to the financial statements, which would substantially
duplicate the disclosure contained in the audited financial statements for 2003
as reported in the 10-KSB, have been omitted.

NOTE 2 - CONVERTIBLE NOTES PAYABLE


In October 2003, IQ Biometrix issued to three investors its 6% convertible
debentures in the aggregate principal amount of $200,000. The convertible
debentures are due in one year, and convertible at anytime by the holder into IQ
Biometrix common stock at a conversion price of $0.64 per share. In connection
with this issuance, IQ Biometrix issued to the investors warrants to purchase
160,000 shares of IQ Biometrix common stock at an exercise price of $1.25 per
share.

Under generally accepted accounting principles, IQ Biometrix is required to
record the value of the beneficial conversion feature of these convertible
debentures as a debt discount. In addition, the value of the warrants using the
Black Scholes pricing method is also recorded as a debt discount. The total debt
discount recorded with respect to these convertible debentures during the
quarter ended December 31, 2003 was $180,262. This debt discount will be
amortized and charged to interest expense over the term of the respective
debentures. In the event the investors convert the debentures prior to their
maturity, then generally accepted accounting principles require IQ Biometrix to
expense the unamortized balance of the debt discount in full during the period
in which the debentures were converted.


NOTE 3 - STOCK ISSUANCES


During the three and six month periods ended December 31, 2003, IQ Biometrix
issued:

*    272,840  shares for $31,700 in cash as part of an option  exercise of which
     80,000  shares were  exercised  for $1,700 in the three month period ending
     December  31,  2003 and 42,840 were  exercised  in  exchange  for  services
     rendered.

*    2,638,669  shares to  consultants  for  corporate  development,  marketing,
     investment banking, investor relations and sales support services valued at
     $2,382,431 of which 741,846  shares worth $821,072 were issued in the three
     month period ending December 31, 2003.

*    119,637  shares to a board  member as payment for  consulting  services and
     expense  reimbursements  valued at $123,264  were issued in the three month
     period ended December 31, 2003.

*    71,111 shares in payment of intellectual property valued at $80,000.

*    60,000 shares in payment of accrued but unpaid  interest  valued at $55,800
     were issued in the three month period ended December 31, 2003.

*    700,000 shares issued related to accrued stock issuance  totaling  $168,000
     at June 30, 2003.



NOTE 4 - SUBSEQUENT EVENTS:


On January 15, 2004, Michael Walsh joined the Company as its Chief Financial
Officer, Treasurer and Controller. In February 2004, the Company extended the
maturity date of the $300,000 debenture held by Special Equity IV LP, which was
originally due on April 1, 2004 to September 30, 2004. On March 26, 2004 Morden
C. Lazarus stepped down from the Company's Board of Directors and Daniel P.
McKelvey was appointed to the Company's Board of Directors. Daniel P. McKelvey
is a managing member of Forte Capital Partners LLC, which is the general partner
of Special Equity IV L.P. Both Forte Capital Partners LLC and Special Equity IV
L.P. are the beneficial holders of shares of the Company's Common Stock.


                                       6

<PAGE>


ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION

FORWARD-LOOKING STATEMENTS

In addition to historical information, this report contains predictions,
estimates and other forward-looking statements within the meaning of Section 27A
of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act
of 1934 that relate to future events or our future financial performance. These
statements involve known and unknown risks, uncertainties and other factors that
may cause our actual results, levels of activity, performance or achievements to
be materially different from any future results, levels of activity, performance
or achievements expressed or implied by the forward-looking statements. These
risks and other factors include those listed under "Risk Factors" and elsewhere
in this Registration Statement, and some of which we may not know. In some
cases, you can identify forward-looking statements by terminology such as "may,"
"will," "should," "expects," "plans," "anticipates," "believes," "estimates,"
"predicts," "potential," "continue" or the negative of these terms or other
comparable terminology. In addition, these forward-looking statements include,
but are not limited to, statements regarding the following:

*    our belief that our FACES(TM)  technology  will help solve the growing need
     for  effective  tools to fight  crime  and  terrorism  as well as  offering
     potential applications relating to other industries;

*    our belief that our InterCode(TM)  coding system is a breakthrough  feature
     that can serve as the first  international  standard in the  generation  of
     unique alphanumeric codes for facial recognition data;

*    our belief that  international  markets represent a significant  market for
     our products and services;

*    our  belief  that we  have  ample  room to  penetrate  further  the  public
     security/law enforcement agencies segment of the market;

*    our intention to compete  vigorously in terms of price,  product  features,
     product  performance,  ease of use,  quality of support  and  service,  and
     company reputation;

*    our  expectations  regarding  the  sources  from which we will  finance our
     operations;

*    our expectations regarding the amount of funds we will need in the future;

*    our  expectations  regarding the focus of our sales efforts on our existing
     customers;

*    our expectations  regarding the amount of additional  development  expenses
     needed to pursue our research and development strategy;

*    our  expectations  regarding  the timing of the rollout,  release or public
     availability of any products of ours now or hereafter under development;

*    our  expectations  regarding our receipt of revenues from training users of
     our products;

*    our intentions and  expectations  regarding the future  availability of now
     undeterminable revenue opportunities arising out of our technology;

*    our  expectations  regarding the abilities and use in certain  locations of
     our FACES(TM) technology;

*    our intentions regarding the protection of our proprietary information;

*    our expectations and intentions regarding our ability to make available the
     finest facial composite technology on the market;

*    our intentions  regarding the continued  development  and refinement of our
     existing  products,  and the development and  commercialization  of various
     computer programs and products using the InterCode(TM) technology;

*    our intentions  regarding the  continuation of our direct selling  efforts;
     and

*    our intentions regarding our marketing and sales efforts.

These statements are only predictions and are subject to risks and
uncertainties, including the following:

*    the  difficulty of forecasting  revenues due to weakness and  uncertainties
     related  to general  economic  conditions  and  overall  demand  within our
     markets and among our current and prospective customers;

*    our ability to introduce and gain customer  acceptance of new products on a
     timely basis;

                                        7

<PAGE>

*    the availability and timely distribution of governmental funding;

*    our  ability to obtain  additional  debt or equity  financing  at all or on
     reasonable terms;

*    the failure to execute on our acquisition and partnering strategies and our
     expansion  into  potential new markets,  which may prevent  achievement  of
     profitability in a timely manner;

*    our ability to introduce and gain customer  acceptance of new products on a
     timely basis;

*    the protection of our proprietary technology

*    unforeseen  development  delays for new products  that limit our ability to
     generate revenues;

OVERVIEW

IQ Biometrix, Inc. is a provider of biometric software and services primarily to
law enforcement agencies and the security industry and is headquartered in
Fremont, California. IQ Biometrix markets, distributes and sells a facial
composite software tool called FACES(TM) to federal, state and local law
enforcement agencies and the security industry in the United States and abroad.


During fiscal year 2003 we derived substantially all of our revenues from sales
of our FACES(TM) 3.0 product. In July 2003, we launched FACES(TM) 4.0. FACES(TM)
4.0 contains significant enhancements and new features over FACES(TM) 3.0,
including the ability to use the TRAK service offered by SocialTech, Inc., which
allows any police officer to create high-resolution photo bulletins and share
them electronically with other law enforcement jurisdictions, the media, and the
community where appropriate. Revenues in fiscal year 2002 and 2003 were derived
from a diverse customer base sold mainly in units of 1 to 50. No customer was
responsible for more than 2% of revenues. Approximately 85% of the increase in
our revenues for this period was due to an increase in our licensing fee,
although the number of licenses sold decreased by approximately 25%.


We market and sell our products both directly through our own sales force as
well as indirectly through resellers and distributors in the United States. To
date, most of our sales have been in North America; however, we recently began
to seek relationships with international distributors and resellers to sell our
products internationally. We are continually reviewing our sales and
distribution strategy to seek ways to increase sales of our product and
revenues.

Cost of revenues currently consists of inventory and packaging costs.

Sales and marketing expenses consist primarily of salaries, commissions and
related expenses for personnel engaged in marketing, sales and customer support,
as well as costs associated with promotional activities and travel expenses. We
intend to expand our sales and marketing operations and efforts substantially
for our products, both domestically and internationally, in order to increase
market awareness and to generate increased sales of our products. Although, we
cannot be certain that any increased expenditures will result in higher
revenues, we believe that continued investment in sales and marketing is
critical to our success and expect these expenses to increase in absolute
dollars in the future and as a % of revenues.

General and administrative expense consists primarily of salaries and related
expenses for executive, finance, accounting, information technology, facilities,
and human resources personnel. We expect these expenses to increase as we
continue to add personnel and incur additional costs related to the anticipated
growth of our business and to support our operations as a public company. We
expect that these expenses will stabilize in the next six to twelve months as we
meet our immediate staffing needs. We expect these expenses to increase in
absolute dollars but be less in the future as a % of revenue.

Research and development expense consists primarily of salaries and related
personnel expense, fees paid to consultants and outside service providers, and
other expenses related to the design, development, testing and enhancement of
our products. Currently we are focusing our attention on is on FACES 5.0. We are
also continually seeking other products and intellectual property that could be
used to enhance our current product and/or product line. We expense our research
and development costs as they are incurred. We believe that a significant level
of investment for product research and development is required to remain
competitive. Accordingly, we expect to continue to devote substantial resources
to product research and development, and we expect our research and development
expense to continue to increase in the future both in absolute dollars and as a
% of revenue.

RESULTS OF OPERATIONS


Revenues increased 181% to $138,000 for the six months ended December 31, 2003
from $49,000 for the six months ended December 31, 2002. In the three months
ended December 31, 2003 revenues increased 95% to $55,000 as compared to $28,000
for the three months ended December 30, 2002. Revenues increased in the relevant
periods primarily because we released our new FACES(TM) version 4.0 in July of
2003 and substantially increased our license fee. Approximately 85% of the
increase in our revenues for this period was due to an increase in our licensing
fee, although the number of licenses sold decreased by approximately 25%. As of
December 31, 2003 approximately 60% of our revenues are derived from sales to
new customers and 40% are derived from sales of upgrades to existing customers.
2003 revenues were derived primarily from the sale of FACES(TM) 4.0 while 2002
revenues were from the sale of our FACES(TM) version 3.1 and FACES(TM) version
LE products.


                                       8
<PAGE>

Sales and marketing expense increased 113% to $181,000 for the six months ended
December 31, 2003 from $86,000 for the six months ended December 31, 2002. The
increase was due to increased promotions and marketing expenses incurred in
conjunction with the release of FACES 4.0. Of these expenses, $181,000 were paid
with common stock. In the three months ended December 31, 2003 sales and
marketing expense decreased to $32,000 a slight decrease from $37,000 for the
three months ended December 31, 2002. Sales and marketing expense decreased due
to the completion of the launch of FACESTM 4.0 in the prior quarter.

General and administrative and consulting expense increased 276% to $2,300,514
for the six months ended December 31, 2003 from $611,000 for the six months
ended December 31, 2002. In the three months ended December 31, 2003, general
and administrative and consulting expense increased 164% to $869,000 from
$329,000. The increased spending was mainly for investor relations of $291,000,
investment banking fees of $726,000, legal fees of $563,000, and payroll of
$190,000. The use of these funds is related to the company's search for
additional sources of capital, partnering or acquisition opportunities and
creating the corporate infrastructure needed in a public company. Of these
expenses, approximately $1,996,000 was paid in the form of shares of our common
stock. The increase in general and administrative expenses, during the three
months ended December 31, 2003, was mainly for investor relations expenses of
$80,000, investment banking fees of $429,000, legal fees of $120,000, and
payroll of $40,000. Of these expenses, approximately $600,000 was paid in the
form of shares of our common stock. The use of these funds is related to the
company's search for additional sources of capital, partnering or acquisition
opportunities. The use of these funds in the three months ended December 31,
2003 was related to the Company's search for additional sources of capital,
partnering or acquisition opportunities.


Research and development expense increased 88% to $150,000 for the six months
ended December 31, 2003 from $80,000 for the six months ended December 31, 2002.
In the three months ended December 31, 2003, research and development expense
increased 11% to $62,000 from $55,000 for the three months ended December 31,
2002. The increase in research and development costs are primarily as a result
of costs incurred in the planning and development of our next generation and
researching products and intellectual property for potential partnering
opportunities. Of these expenses, approximately $150,000 were paid with common
stock. We anticipate research and development expenses for the development of
our next generation product as well as our ongoing analysis of third party
products and intellectual property to approach $250,000 in fiscal 2004.


Interest expense increased 8,766% to $734,489 for the six months ended December
31, 2003 from $19,000 for the six months ended December 31, 2002. In the three
months ended December 31, 2003 interest expense increased 1,437% to $408,381
from $9,000 for the three months ended December 31, 2002. All increases are
related to the amount of issued debt of $1,800,000 compared to $200,000 at
December 31, 2003 and 2002, respectively and the amortization of the debt
discounts in 2004.

LIQUIDITY AND CAPITAL RESOURCES

As of December 31, 2003, we had cash and cash equivalents of approximately
$374,000. Net cash used in operations decreased to $353,131 for the six months
ended December 31, 2003 compared with $599,000 for the six months ended December
31, 2002. The $246,000 improvement was primarily the result of the issuance of
2,638,669 shares of common stock issued in lieu of cash for services of
$2,382,43, amortization of debt discount of $540,000 offset by the paydown of
payables and accrued liabilities of $320,000.

Net cash provided by financing activities was about the same at $582,000 for the
six months ended December 31, 2003 compared with $600,000 for the six months
ended December 31, 2003.

From our inception in 2002 we have financed our operations primarily through
private sales of common stock and convertible debentures. We have negative
working capital totaling $910,000 which consists of $1,208,442 of convertible
investor notes, which is net of debt discounts totaling $591,558.

There is a "Going Concern" reservation in our auditor's opinion for the year
ended June 30, 2003. We are currently seeking sources of capital as we believe
we may have trouble meeting and servicing our current operating cash flow
requirements in the next four to six months. At December 31, 2003 we had cash of
$374,000; accounts payable of $44,000, and accrued liabilities of $107,505.

                                        9

<PAGE>

By June 1, 2004, $850,000 of the convertible notes become due and payable. We
have no assurances that these notes will be converted into common stock per the
terms of the debentures. We currently have no borrowings available to us under
any credit arrangement, and we will look for additional debt and equity
financings should cash provided from operations be insufficient to support our
debt obligations and our ongoing operations of the business. Adequate funds may
not be available on terms acceptable to us. If additional funds are raised
through the issuance of equity securities, dilution to existing stockholders may
result. If funding is insufficient at any time in the future, we may be unable
to develop or enhance our products or services, take advantage of business
opportunities or respond to competitive pressures, any of which could have a
material adverse effect on our financial position, results of operations and
cash flows. The Company has no material commitments for capital expenditures and
there are no anticipated material capital expenditures that are reasonably
expected to have a material impact on the Company.

Even with financing, there can be no assurance that we will achieve
profitability. Due to these factors, we believe that period-to-period
comparisons of our results of operations are not necessarily a good indication
of future performance. The results of operations in some future periods may be
below the expectations of analysts and investors.

We expect operating losses and negative operating cash flows to continue for at
least the next twelve months, because of expected increases in expenses related
to brand development; marketing and other promotional activities; increases in
personnel; the expansion of infrastructure and customer support services;
strategic relationship development; and potential acquisitions of related
complementary businesses. We believe the expenses incurred here will help us to
build the infrastructure necessary to increase revenues both through organic
growth and through acquisitions, which we believe hold the key to our future
revenue growth. We feel it will take additional products, either created in
house or acquired through acquisitions, to help us increase revenue, and
ultimately to reach profitability. However, we can make no assurances that these
activities will achieve the desired results of increased revenues, nor that any
increase in revenues will be enough to bring the company to profitability and
positive cash flow.

                                       10

<PAGE>

RECENT EVENTS


On January 15, 2004, Michael Walsh joined the Company as its Chief Financial
Officer, Treasurer and Controller. In February 2004, the Company extended the
maturity date of the $300,000 debenture held by Special Equity IV LP, which was
originally due on April 1, 2004 to September 30, 2004. On March 26, 2004 Morden
C. Lazarus stepped down from the Company's Board of Directors and Daniel P.
McKelvey was appointed to the Company's Board of Directors. Daniel P. McKelvey
is a managing member of Forte Capital Partners LLC, which is the general partner
of Special Equity IV L.P. Both Forte Capital Partners LLC and Special Equity IV
L.P. are the beneficial holders of shares of the Company's Common Stock.


CRITICAL ACCOUNTING POLICIES

INTANGIBLE ASSETS

Our intangible assets consist of a customer list acquired in the JVWEB / IQ
Biometrix acquisition in March 2002 and purchased software code. We recorded the
cost of the software and amortize the cost over the estimated useful life of 3
years. We review the value of our intangible assets quarterly and determine its
value. At December 31, 2003 we had a net carrying value for our intangible
assets of $126,000.

REVENUE RECOGNITION

We adopted revenue recognition policies to comply fully with the guidance in
Staff Accounting Bulletin No. 101, "Revenue Recognition in Financial
Statements." Revenue consists of shipped customer orders and completed services.
We have an increasing sale order backlog, however those orders are not
considered revenue until the order is shipped and services are rendered.

We account for the licensing of software in accordance with American Institute
of Certified Public Accountants (AICPA) Statement of Position (SOP) 97-2,
Software Revenue Recognition. The application of SOP 97-2 requires judgment,
including whether a software arrangement includes multiple elements, and if so,
whether vendor-specific objective evidence (VSOE) of fair value exists for those
elements. Changes to the elements in a software arrangement, the ability to
identify VSOE for those elements, the fair value of the respective elements, and
changes to a product's estimated life cycle could materially impact the amount
of earned and unearned revenue. Judgment is also required to assess whether
future releases of certain software represent new products or upgrades and
enhancements to existing products.

INFLATION

In our opinion, inflation has not had a material effect on our operations.

CONTROLS AND PROCEDURES


The Company maintains disclosure controls and procedures that are designed to
ensure that information required to be disclosed in the Company's Exchange Act
reports is recorded, processed, summarized and reported within the time periods
specified in the SEC's rules and forms, and that such information is accumulated
and communicated to the Company's management, including its Chief Executive
Officer/Chief Financial Officer, as appropriate, to allow timely decisions
regarding required disclosure based closely on the definition of "disclosure
controls and procedures" in Rule 13a-14(c). In designing and evaluating the
disclosure controls and procedures, management recognized that any controls and
procedures, no matter how well designed and operated, can provide only
reasonable assurance of achieving the desired control objectives, and management
necessarily was required to apply its judgment in evaluating the cost-benefit
relationship of possible controls and procedures. The Company maintains that the
controls and procedures in place do provide reasonable assurance that all
necessary disclosures are communicated as required.


At the end of the period covered by this Quarterly Report, the Company carried
out an evaluation, under the supervision and with the participation of the
Company's management, including the Company's Chief Executive Officer/Chief
Financial Officer, of the effectiveness of the design and operation of the
Company's disclosure controls and procedures. Based on the foregoing, the
Company's Chief Executive Officer and Chief Financial Officer concluded that the
Company's disclosure controls and procedures were effective to ensure that all
material information required to be filed in this Quarterly Report has been made
known to them in a timely fashion.


There have been no significant changes in the Company's internal controls or in
other factors that could significantly affect the internal controls subsequent
to the date the Company completed its evaluation.


                                       11
<PAGE>

RISK FACTORS

RISKS RELATED TO OUR FINANCIAL RESULTS

WE CURRENTLY LACK LIQUIDITY AND WE WILL NEED TO RAISE ADDITIONAL EQUITY OR DEBT
FINANCING TO FUND OUR OPERATIONS.

To date, we have had no meaningful revenues and there is a "Going Concern"
reservation in our auditor's opinion for the year ended June 30, 2003. We have
heretofore financed our business through the procurement of capital investments.
At December 31, 2003, we had cash, cash equivalents and short-term investments
of $374,000; our accounts payable were approximately $44,000, and we had accrued
expenses of $86,000. In September and October 2003 we raised an additional
$700,000 through the issuance of convertible debentures, which mature in 2004.
In order to address our immediate liquidity issues, we are seeking additional
debt or equity financing. We currently do not have any credit arrangements. We
may not be able to obtain additional debt or equity financing. If successful in
raising additional financing, we may not be able to do so on terms that are not
excessively dilative to existing stockholders or less costly than existing
sources of financing. Failure to secure additional financing in a timely manner
and on favorable terms in the future could have a material adverse impact on our
financial performance and stock price and require us to implement certain cost
reduction initiatives and curtail our operations.

In addition, any financing arrangement may have potentially adverse effects on
us or our stockholders. Debt financing (if available and undertaken) may involve
restrictions limiting our operating flexibility. Moreover, if we issue equity
securities to raise additional funds, the following results may occur:

*    The percentage ownership of our existing stockholders will be reduced;

*    Our stockholders may experience  additional  dilution in net book value per
     share;

*    The new equity securities may have rights, preferences or privileges senior
     to those of the holders of our common stock.

We are seeking to increase our revenues by increasing sales of our existing
products through the expansion of our marketing program and our sales force. We
are also exploring the development of new products that are synergistic to our
existing business and actively seeking out acquisition and partnering prospects
that would complement our existing product offerings, augment our market
coverage, or enhance our technological capabilities. There can be no assurance
that we will be successful in increasing sales of our existing products,
developing or locating new products, or consummating any acquisitions or
partnering transactions. Even if we were able to develop or acquire new
products, there can be no assurance that sales of these new products would
result in increased revenues, in which case our business, results of operations
and financial condition would be materially and adversely affected.


OUR LIMITED OPERATING HISTORY MAKES AN EVALUATION OF US AND OUR FUTURE EXTREMELY
DIFFICULT.

We have only recently begun selling our FACES(TM) 4.0 product, and we have
generated very limited revenues from its sale. Because we have only recently
begun to generate revenues, we are unable to accurately forecast what the level
of our revenues will be, and we have limited meaningful historical financial
data upon which to plan future operating expenses. Given our extremely limited
revenues to date and our current limited cash resources, if our revenues in any
period are lower than we project, our business, results of operations and
financial condition would be materially and adversely affected. In addition, our
ability to forecast accurately our quarterly revenue and expenses is limited due
to a number of factors, including:

*    The fact that we currently  derive  substantially  all of our revenues from
     sales of our FACES (TM) software  product and our expectation  that we will
     continue to derive  substantially all of our revenues from this product for
     the foreseeable future;

*    The market's limited acceptance of our product to date;

*    Our ability to develop and increase our customer base;

*    Our need to expand our distribution capability;

*    Our ability to implement and  successfully  execute our sales and marketing
     strategy;

*    Our need to introduce new products and services to respond to technological
     and competitive developments and customer needs;

*    Our ability to manage the growth we are seeking to realize;

*    Our ability to respond to competitive developments;

*    Our dependence on our current executive officers and key employees;

*    Our ability to provide superior customer service and order fulfillment.

                                       12
<PAGE>

There can be no assurance that we can successfully address some or all of these
risks but our failure to do so could materially and adversely affect our
business, prospects, financial condition and results of operations.

WE HAVE A HISTORY OF LOSSES AND DO NOT KNOW WHEN WE MAY BECOME PROFITABLE OR IF
WE DO BECOME PROFITABLE WHETHER WE CAN SUSTAIN PROFITABILITY.

We have incurred net losses of $8,178,385 since inception. As of December 31,
2003, we had an accumulated stockholder deficit of $776,227 million and we
expect to continue to incur net losses for the foreseeable future. We also
expect to incur significant product development, sales and marketing and general
and administrative expenses. As a result, we will need to generate increased
revenues to achieve profitability and we may not be able to generate sufficient
revenues to achieve profitability. To increase our revenues, we must increase
sales of our existing products and introduce new products that we have either
developed internally or acquired through other arrangements. While we believe we
can grow our revenues from our existing product through internal actions, the
rate of growth will most likely not allow us to achieve our breakeven quarterly
revenue level in a timely manner. Therefore, we continue to evaluate business
combinations and partnering arrangements in our core business areas that would
improve our market share position, increase our revenue, improve on our net loss
position and accelerate our ability to reach profitability. While we are seeking
acquisitions that we believe would improve our financial results, a completed
acquisition may not provide the anticipated financial results, thus leading to
continuing net losses. Even if we achieve profitability, we may not be able to
sustain or increase profitability on a quarterly or annual basis. We are seeking
to increase our revenues by increasing the sales of our existing products
through the expansion of our marketing program and our sales force. We are also
exploring the development of new products that are synergistic to our existing
business and actively seeking out acquisition and partnering prospects that
would complement our existing product offerings, augment our market coverage, or
enhance our technological capabilities. There can be no assurance that we will
be successful in increasing sales of our existing products or in developing or
locating new products. Even if we were able to develop or acquire new products,
there can be no assurance that sales of these new products would result in
increased revenues, in which case our business, results of operations and
financial condition would be materially and adversely affected.

FLUCTUATIONS IN OUR BUSINESS AND OPERATING RESULTS MAY MATERIALLY AND ADVERSELY
AFFECT THE TRADING PRICE OF OUR COMMON STOCK.

We expect that our operating results will fluctuate in the future due to a
number of factors many of which are outside of our control. These factors
include the following:

*    Customer  concentration;  most of our current and prospective customers are
     local,  state  and  federal  law  enforcement  agencies,  many of which are
     experiencing their worst budget crisis in years;

                                       13

<PAGE>

*    Budgetary cycles of governmental agencies;

*    Overall demand for our products;

*    Our ability to attract new customers at a steady rate;

*    The rate at which we or our competitors introduce new products, the rate at
     which these products  acquire market  acceptance,  and the cost required to
     develop these products;

*    Technical  defects in our products  that could delay  product  shipments or
     increase the costs of introducing new products;

*    Changes in the pricing of our products or those of our competitors;

*    The amount and timing of capital  expenditures  and other costs relating to
     the expansion of our operations;

*    Costs relating to our marketing programs and our business in general;

*    General economic conditions.

Any of the foregoing factors may cause our operating expenses to be
disproportionately high or cause our revenue and operating results to fluctuate
causing our business, financial condition and operating results to be adversely
affected. In addition, to respond to changes in our competitive environment, we
may occasionally make certain decisions from which we may benefit in the long
run. However, in the short run, such decisions could materially and adversely
affect our quarterly results of operations and financial condition. Due to all
of the foregoing factors, in some future quarter our operating results may fall
below our expectations and those of our stockholders. In such event, the trading
price of our common stock could be materially adversely affected. Further, we
believe that period-to-period comparisons of our financial results may not be
very meaningful. Accordingly, you should not conclude that such comparisons
indicate future performance.

                                       14
<PAGE>

RISKS RELATED TO OUR BUSINESS

OUR BUSINESS WILL NOT GROW UNLESS THE MARKET FOR BIOMETRIC SOLUTIONS EXPANDS
BOTH DOMESTICALLY AND INTERNATIONALLY.

Our revenues are derived from the sale of biometric products. Biometric
solutions have not gained widespread commercial acceptance. We cannot accurately
predict the future growth rate, if any, or the ultimate size of the biometric
technology market. The expansion of the market for our products and services
depends on a number of factors including without limitation:

o    the cost,  performance and reliability of our products and services and the
     products and services of competitors;

o    customers' perception of the perceived benefit of biometric solutions;

o    public  perceptions of the  intrusiveness of these solutions and the manner
     in which firms are using the information collected;

o    public perceptions regarding the confidentiality of private information;

o    proposed or enacted legislation related to privacy of information;

o    customers' satisfaction with our products and services; and

o    marketing efforts and publicity regarding these products and services.

IF WE FAIL TO GENERATE REPEAT OR EXPANDED BUSINESS FROM OUR CURRENT AND
PROSPECTIVE CUSTOMERS, OUR BUSINESS WILL BE SERIOUSLY HARMED.

We believe that our success will depend on the continued  growth of our customer
base as well as the sale of new and enhanced products to our existing customers.
Over 150,000  licenses to pre-4.0  versions of our  FACES(TM)  product have been
distributed  to law  enforcement  agencies in the United States and we expect to
focus a large part of our sales and  marketing  efforts  with respect to our new
products on these existing  customers.  If we are to be successful in generating
sales from our existing  customers,  we will need to convince  them that our new
products  provide them with  additional  benefits.  In addition,  our ability to
attract  new  customers  will  depend on a variety  of  factors,  including  the
reliability  and   cost-effectiveness   of  our  products  and  our  ability  to
effectively  market our  products.  If we fail to generate  repeat and  expanded
business from our current and prospective customers,  our operating results will
be seriously harmed.

IF WE FAIL TO PROMOTE OUR BRAND NAME SUCCESSFULLY OR IF WE INCUR SIGNIFICANT
EXPENSES PROMOTING AND MAINTAINING OUR BRAND NAME, OUR BUSINESS COULD BE HARMED.

Due in part to the emerging nature of the market for our products and the
substantial resources available to some of our competitors, there may be a
limited time opportunity for us to achieve and maintain a significant market
share. Developing and maintaining awareness of our brand name is critical to
achieving widespread acceptance of our products. Furthermore, we believe that
the importance of brand recognition will increase as competition in the market
for products such as ours increases. Successfully promoting and positioning our
brand will depend largely on the effectiveness of our marketing efforts. To
attract and retain customers and to promote and maintain our brands in response
to competitive pressures, we may need to increase our marketing budget or
otherwise to increase substantially our financial commitment to creating and
maintaining brand loyalty among vendors and consumers. If we are unable for
financial reasons to increase our sales and marketing budget or if we are unable
to successfully promote our brand, our business will suffer.

                                       15
<PAGE>

OUR REVENUES ARE DEPENDENT UPON THE AVAILABILITY AND TIMELY DISTRIBUTION OF
GOVERNMENTAL FUNDING.

Many of our prospective customers are local, state and federal law enforcement
and other governmental and quasi-governmental agencies. The ability of these
prospective customers to purchase our products are heavily dependent on the
availability or continued availability of federal, state or local government
funds or grants and general tax funding, including funding by the Office of
Homeland Security. Such funding may not be approved or, if approved, it may not
be available for the purchase of our products or solutions, and even if such
funding is approved and available, such funds may be subject to termination at
any time at the sole discretion of the government body providing or receiving
such funds.

RAPID TECHNOLOGICAL CHANGE IN OUR MARKET COULD CAUSE OUR PRODUCTS TO BECOME
OBSOLETE OR REQUIRE US TO REDESIGN OUR PRODUCTS.

We expect that our market will be characterized by rapid technological change,
frequent new product introductions and enhancements, uncertain product life
cycles, changing customer demands and evolving industry standards, any of which
can render existing products obsolete. We believe that our future success will
depend in large part on our ability to develop new and effective products in a
timely manner and on a cost effective basis. As a result of the complexities
inherent in our product, major new products and product enhancements can require
long development and testing periods, which may result in significant delays in
the general availability of new releases or significant problems in the
implementation of new releases. In addition, if we or our competitors announce
or introduce new products our current or prospective customers may defer or
cancel purchases of our products, which could materially adversely affect our
business, operating results and financial condition. Our failure to develop
successfully, on a timely and cost effective basis, new products or new product
enhancements that respond to technological change, evolving industry standards
or customer requirements would have a material adverse affect on our business,
operating results and financial condition.

IF WE LOSE ANY KEY PERSONNEL, OR FAIL TO ATTRACT AND RETAIN ADDITIONAL
PERSONNEL, WE MAY BE UNABLE TO CONTINUE DEVELOPING OUR BUSINESS AND PRODUCT
LINE.

The loss of the services of one or more of our key personnel could materially
adversely affect our business, operating results and financial condition. We
cannot guarantee that we will be able to retain our key personnel. Our future
success also depends on our continuing ability to attract, assimilate and retain
highly qualified sales, technical and managerial personnel. Competition for
these individuals is intense, and there can be no assurance that we can attract,
assimilate or retain necessary personnel in the future.

FAILURE TO EXPAND OUR SALES AND DISTRIBUTION CHANNELS AND MANAGE OUR SALES AND
DISTRIBUTION RELATIONSHIPS COULD SIGNIFICANTLY REDUCE OUR REVENUES.

We sell our products through a network of distributors and resellers. Our
success will depend on our ability to manage relationships with our existing
network of distributors and resellers and to expand our network of resellers and
distributors. The sale of our products by our distributors and resellers depends
on the effectiveness of their selling efforts and their ability to meet their
own responsibilities under agreements with customers in a timely manner. At
times, our distributors and resellers may also offer products of our competitors
and our agreements with them have no minimum purchase commitments. We cannot
assure you that we will be able to expand our distribution channels, manage our
distribution relationships successfully or that our distributors and resellers
will market and sell our products effectively. Our failure to manage
successfully our distribution relationships or the failure of our distributors
and resellers to sell our products could reduce our revenues and have a material
adverse effect on business, results of operations and financial conditions.

RISKS RELATED TO DEVELOPING OUR PRODUCTS

SUBSTANTIALLY ALL OF THE SOFTWARE DEVELOPMENT FOR OUR FACES(TM) 4.0 PRODUCT WAS
OUTSOURCED TO A THIRD PARTY. IF WE CONTINUE TO USE THIRD PARTY DEVELOPERS FOR
FUTURE PRODUCT RELEASES WE MAY IN THE FUTURE BE SUBJECT TO DELAYS IN PRODUCT
RELEASES, ENHANCEMENTS AND UPGRADES AS WELL AS QUALITY CONTROL ISSUES.

We outsourced the development of our FACES(TM) 4.0 software to Entreprise
Cogniscience, Inc. an independent software developer. Although, FACES(TM) 4.0
was commercially released in 2003, we have discovered and we may continue to
discover errors and defects in FACES(TM) 4.0. The fact that we do not directly
control the development of our product subjects us to the risk that we may
experience delays in issuing error corrections or enhancements to our most
recent release. Recently, Entreprise Cogniscience was acquired by a third party.
While, the agreement between us and Entreprise Cogniscience is binding upon any
successor-in-interest to Entreprise Cogniscience, we cannot guarantee that the
acquiror will devote as many resources to fulfilling the agreement as Entreprise
Cogniscience did before the acquisition or that the quality of their work will
meet our specifications. If the successor-in-interest fails to devote as many
resources to our product or if the quality of their work does not meet our
specification, it could lead to delays in releasing any error corrections or bug
fixes. In addition, if we continue to use Entreprise Cogniscience or another
independent software developer to develop future releases or products, we may
experience delays in future product releases, enhancements and upgrades, as well
as difficulties in maintaining quality control which may lead to higher than
expected error and defect rates, all of which could have an adverse effect on
our business, results of operations and financial condition.

WE DEPEND ON THIRD-PARTY TECHNOLOGY FOR THE DEVELOPMENT OF OUR SOFTWARE. IF WE
WERE TO TERMINATE OUR RELATIONSHIP WITH SUCH THIRD PARTY PROVIDER, WE COULD
EXPERIENCE DELAYS IN FUTURE PRODUCT RELEASES AND IMPROVEMENTS PRODUCTS.

Entreprise Cogniscience, the third party software developer that assisted us in
the development of FACES(TM) 4.0, used a proprietary environment based on LISP
to develop our software. If we were to bring our software development in-house
or if our relationship with Entreprise Cogniscience were otherwise to terminate,
we would need to port our source code to a new development environment, which
may cause us to experience delays in future product releases, enhancements and
upgrades, as well as higher than expected error and defect rates, all of which
could have an adverse effect on our business, results of operations and
financial condition.

OUR SOFTWARE PRODUCTS ARE COMPLEX AND MAY CONTAIN UNKNOWN DEFECTS THAT COULD
RESULT IN NUMEROUS ADVERSE CONSEQUENCES.

Complex software products such as ours often contain latent errors or defects,
particularly when first introduced, when new versions or enhancements are
released and when configured for a specific customer. We currently have
experienced errors and defects in our most recent release. However, there can be
no assurance that despite testing, defects and errors will not be found in
current versions, new versions or enhancements of our products after
commencement of commercial shipments, any of which could result in damage to our
reputation, the loss of sales, a diversion of our product development resources,
or a delay in market acceptance, and thereby materially adversely affecting our
business, operating results and financial condition. The computer hardware
environment is characterized by a wide variety of non-standard configurations
that make prerelease testing for programming or compatibility errors very
difficult and time consuming. Despite our testing, errors may still be
discovered in some new products or enhancements after the products or
enhancements are delivered to customers. Furthermore, there can be no assurance
that our products will meet all of the expectations and demands of our
customers. The failure of our products to perform to customer expectations could
give rise to warranty claims. Any of these claims, even if not meritorious,
could result in costly litigation or divert management's attention and
resources. We do not currently maintain any general liability insurance. Any
general liability insurance that we may carry could be insufficient to protect
us from all liability that may be imposed under any asserted claims. Although
through our license agreements with customers we try to include provisions
designed to limit our exposure to potential claims, such limitation of liability
provisions may not be effective as a result of existing or future laws or
unfavorable judicial decisions.

                                       16
<PAGE>

We outsource the packaging of our product, which consists of transferring our
FACES(TM) software onto compact discs, quality control testing and packaging the
CDs and manuals, to Stephen Gould Corporation in Sacramento, CA. There are a
number of software packaging companies that we could use in the event our
current vendor becomes unavailable. We have multiple sources for compact discs.
Quality control tests are selectively performed on finished products. We also
outsource our product fulfillment to OnFullfillment Inc. in Newark, CA, which
stores inventory, packages and ships orders.

We presently manage all our own information processing, vendor management,
logistics services, licensing, and related supporting functions from our
Fremont, California office.

IF THE USE OF OUR PRODUCTS IS DEEMED TO BE AN INVASION OF PERSONAL PRIVACY
RIGHTS OUR BUSINESS MAY SUFFER.

From time to time, biometric products such as ours have been the focus of
organizations and individuals seeking to curtail or eliminate the use of these
technologies on the grounds that these technologies may be used to diminish
personal privacy rights. In the event that such initiatives result in
restrictive legislation, the market for products such as ours may be adversely
affected.

IF WE GROW OUR BUSINESS AS PLANNED, WE MAY NOT BE ABLE TO MANAGE PROPERLY OUR
GROWTH, WHICH MAY IMPEDE OUR ABILITY TO ACHIEVE PROFITABILITY.

If we are successful in growing our business as we plan, our operations may
expand rapidly and significantly. Any rapid growth could put a significant
strain on our management, operational and financial resources. In order to
manage the growth of our operations, we will be required to expand existing
operations, to implement new operational, financial and inventory systems,
procedures and controls, including improvement of our financial and other
internal management systems, and to hire, train, manage and expand our employee
base. If we are unable to manage growth effectively, our business, results of
operations and financial condition will be materially adversely affected. In
addition, if we are successful in growing our business as we plan, we expect
operating expenses to increase, and as a result, we will need to generate
increased revenue to achieve and maintain profitability. In particular, as we
grow our business, we would incur additional costs and expenses related to:

*    The expansion of our sales force and distribution channels;

*    The expansion of our product and services offerings;

*    Development of relationships with strategic business partners;

*    The expansion of management and infrastructure;

*    Brand development, marketing and other promotional activities.

Costs associated with these activities could delay our ability to achieve or
maintain profitability.

OUR ACQUISITION STRATEGY MAY BE UNSUCCESSFUL, WHICH MAY HARM OUR ABILITY TO GROW
REVENUES.

We believe that our future success depends on our ability to introduce and
market new products and services that we have either developed internally or
acquired through strategic combinations or partnering relationships. We intend
to actively seek out acquisition and partnering prospects that would complement
our existing product offerings, augment our market coverage, or enhance our
technological capabilities. This strategy is subject to inherent risks
associated with the potential integration of additional operations, the extent
of management time and attention required, and related costs and expenses
associated with the execution of this strategy.

WE WILL FACE TECHNICAL, OPERATIONAL AND STRATEGIC CHALLENGES THAT MAY PREVENT US
FROM SUCCESSFULLY INTEGRATING BUSINESSES WE MAY ACQUIRE IN THE FUTURE.

Execution of our acquisition and partnering strategy could result in a number of
financial consequences, including without limitation:

*    Use of cash resources that would reduce our financial reserves;

*    Issuance of stock that would dilute our current stockholders' percentage
     ownership;

*    Incurrence of debt;

*    Assumption of liabilities;

*    Increased operational and administrative complexity of our business;

*    Higher fixed expenses, which require a higher level of revenues to maintain
     gross margins; and

*    Incurrence of expenses related to in-process research and development and
     the possible impairment of goodwill and other intangible assets, which
     could result in large one-time write-offs.

Furthermore, acquisitions involve numerous operational risks, including:

*    Problems related to the integration and management of acquired technology,
     products, operations, information systems and personnel of the acquired
     company;

*    Problems completing product development programs of the acquired company
     and consolidating research and development efforts;

*    Unanticipated costs or liabilities;

*    Diversion of management's attention from our core business;

*    Diversion of resources from our existing business, products or
     technologies;

                                       17

<PAGE>

*    Adverse effects on existing business relationships with suppliers and
     customers;

*    Risks associated with entering markets in which we have no or limited prior
     experience; and

*    Potential loss of key employees, particularly those of the acquired
     organizations.

The integration of businesses that we may acquire could be a complex, time
consuming and expensive process. We must operate as a combined organization
utilizing common information and communication systems, operating procedures,
financial controls and human resources practices to be successful. We cannot
guarantee that any future acquisitions will result in sufficient revenues or
earnings to recover our investment in, or expenses related to, these
acquisitions or that any synergies will develop. If we are not successful in
integrating acquired businesses or if expected earnings or synergies do not
materialize, we could be forced to attempt to resell or cease operations of
acquired businesses. In either event, we would likely incur significant expenses
as well as non-cash charges to write-off acquired assets, which could seriously
harm our financial condition and operating results.

RISKS RELATED TO OUR INTELLECTUAL PROPERTY

OUR SUCCESS DEPENDS ON OUR ABILITY TO PROTECT OUR INTELLECTUAL PROPERTY.

Our future success depends upon our proprietary technology. We are protecting
our proprietary information through the use of patent, copyright, trademark,
trade secret laws, confidentiality procedures and contractual provisions.
Notwithstanding our efforts to protect our proprietary technology, policing
unauthorized use or copying of our proprietary information is difficult,
unauthorized use or copying occurs from time to time, and litigation to enforce
intellectual property rights could result in significant costs and diversion of
resources. Any patents we obtain in the future may be circumvented, challenged,
invalidated or designed around by other companies. Despite our efforts, we may
be unable to prevent third parties from infringing upon or misappropriating our
intellectual property. Moreover, the laws of some foreign jurisdictions do not
afford the same degree of protection to our proprietary rights as do the laws of
the United States, and effective trademark, copyright, and trade secret
protection may not be available in every country in which our products are
distributed. Furthermore, our competitors may independently develop similar
technology that substantially limits the value of our intellectual property. Our
inability to protect adequately our intellectual property for these or other
reasons could materially and adversely affect our business, financial condition
and operating results.

In addition, third parties may at some point claim certain aspects of our
business infringe their intellectual property rights. While we are not currently
subject to nor are aware of any such claim, any future claim (with or without
merit) could result in one or more of the following:

*    Significant litigation costs;

*    Diversion of resources, including the attention of management;

*    Our agreement to pay certain royalty and/or licensing fees; and

*    Cessation of our rights to use, market, or distribute such technology.

Any of these developments could materially and adversely affect our business,
results of operations and financial condition. In the future, we may also need
to file lawsuits to enforce our intellectual property rights, to protect our
trade secrets, or to determine the validity and scope of the proprietary rights
of others. Whether successful or unsuccessful, such litigation could result in
substantial costs and diversion of resources. Such costs and diversion could
materially and adversely affect our business, results of operations and
financial condition.

                                       18
<PAGE>

OUR FINANCIAL PERFORMANCE MAY BE ADVERSELY AFFECTED BY COMPETITION.

The market for our products is characterized by significant and increasing
competition. Most of our current and potential competitors have longer operating
histories and significantly greater financial, technical and marketing resources
than we do. We expect competition to intensify in the future as new companies
enter the market on a regular basis. There can be no assurance that existing or
future competitors will not develop or offer products that provide significant
performance, price or other advantages over those we offer. Such a development
could result in price reductions or displacement of our products, which could
materially adversely affect our business, results of operations and financial
condition.

RISKS RELATED TO OUR CORPORATE GOVERNANCE

OUR AUTHORIZED PREFERRED STOCK EXPOSES STOCKHOLDERS TO CERTAIN RISKS.

Our Certificate of Incorporation authorizes the issuance of up to 10,000,000
shares of preferred stock, par value $.01 per share. No shares of preferred
stock have been issued to date. The authorized preferred stock constitutes what
is commonly referred to as "blank check" preferred stock. This type of preferred
stock allows the Board of Directors to divide the preferred stock into series,
to designate each series, to fix and determine separately for each series any
one or more relative rights and preferences and to issue shares of any series
without further stockholder approval. Preferred stock authorized in series
allows our Board of Directors to hinder or discourage an attempt to gain control
of the Company by a merger, tender offer at a control premium price, proxy
contest or otherwise. Consequently, the preferred stock could entrench our
management. In addition, the market price of our common stock could be
materially and adversely affected by the existence of the preferred stock.

OUR COMMON STOCK HAS A LIMITED AND VOLATILE TRADING HISTORY.

Our common stock trades in the United States on the Over-the-Counter Electronic
Bulletin Board (OTCBB). The number of shares traded daily has been extremely
limited and the prices at which our common stock has traded have fluctuated
fairly widely. See "PRICE RANGE OF COMMON STOCK." There can be no assurance as
to the prices at which our common stock will trade in the future, although they
may continue to fluctuate significantly. Prices for our common stock will be
determined in the marketplace and may be influenced by many factors, including
the following:

*    The depth and liquidity of the markets for our common stock;

*    Investor perception of us and the industry in which we operate;

*    General economic and market conditions; and

*    The effect that of any of the events highlighted in these Risk Factors may
     have on our business should they occur.

WE HAVE THE ABILITY AND THE OBLIGATION TO ISSUE ADDITIONAL SHARES OF COMMON
STOCK IN THE FUTURE, AND SUCH FUTURE ISSUANCE MAY MATERIALLY ADVERSELY AFFECT
STOCKHOLDERS.

We have various abilities and obligations to issue additional shares of common
stock in the future. These abilities and obligations include the following:


*    Approximately 970,000 registered shares of our common stock are available
     for issuance to outside consultants to compensate them for services
     provided;

*    Options to purchase approximately 3,656,531 shares of our common stock were
     outstanding as of February 27, 2004;

*    Warrants to purchase approximately 740,000 shares of common stock were
     outstanding as of February 27, 2004;

*    Debentures, convertible into 4,917,750 shares of common stock had been
     issued as of January 31, 2004 and the shares of common stock into which
     such debentures are convertible are being registered as part of this
     registration statement


The options and warrants described above permit the holders to purchase shares
of common stock at specified prices. These purchase prices may be less than the
then current market price of our common stock. Any shares of common stock issued
pursuant to these options or warrants (or the convertible debentures described
above) would further dilute the percentage ownership of existing stockholders.
The terms on which we could obtain additional capital during the life of these
options, warrants or convertible debentures may be adversely affected because of
such potential dilution. Finally, we may issue additional shares in the future
other than as listed above. There are no preemptive rights in connection with
our common stock. Thus, the percentage ownership of existing stockholders may be
diluted if we issue additional shares in the future. For issuances of shares and
grants of options to consultants, our Board of Directors will determine the
timing and size of the issuances and grants, and the consideration or services
required thereof. Our Board of Directors intends to use its reasonable business
judgment to fulfill its fiduciary obligations to our then existing stockholders
in connection with any such issuance or grant. Nonetheless, future issuances of
additional shares could cause immediate and substantial dilution to the net
tangible book value of shares of common stock issued and outstanding immediately
before such transaction. Any future decrease in the net tangible book value of
such issued and outstanding shares could materially and adversely affect the
market value of the shares.

SALES OF OUR COMMON STOCK, INCLUDING THOSE SHARES COVERED BY THIS PROSPECTUS
(WHICH UPON EFFECTIVENESS OF THIS REGISTRATION STATEMENT MAY BE SOLD AT ANY
PRICE AND AT ANY TIME), COULD REDUCE THE PRICE OF OUR COMMON STOCK.

After the registration statement has become effective, the holders of the shares
covered by this prospectus may sell the shares registered pursuant to this
registration statement at any price and at any time determined by them without
limitation. The price of our common stock may be adversely affected upon the
sale of the shares registered hereby.

THE TRADING PRICE OF OUR COMMON STOCK ENTAILS ADDITIONAL REGULATORY
REQUIREMENTS, WHICH MAY NEGATIVELY AFFECT SUCH TRADING PRICE.

The trading price of our common stock is currently below $5.00 per share. As a
result of this price level, trading in our common stock is subject to the
requirements of certain rules promulgated under the Securities Exchange Act of
1934. These rules require additional disclosure by broker dealers in connection
with any trades generally involving any non-NASDAQ equity security that has a
market price of less than $5.00 per share, subject to certain exceptions. Such
rules require the delivery, before any "penny stock" transaction, of a
disclosure schedule explaining the penny stock market and the risks associated
therewith, and impose various sales practice requirements on broker dealers who
sell penny stocks to persons other than established customers and accredited
investors (generally institutions). For these types of transactions, the
broker-dealer must determine the suitability of the penny stock for the
purchaser and receive the purchaser's written consent to the transaction before
sale. The additional burdens imposed upon broker dealers by such requirements
may discourage broker-dealers from effecting transactions in our common stock
affected. As a consequence, the market liquidity of our common stock could be
severely limited by these regulatory requirements.

STOCKHOLDERS HAVE NO GUARANTEE OF DIVIDENDS.

The holders of our common stock are entitled to receive dividends when, as and
if declared by the Board of Directors out of funds legally available therefore.
To date, we have not declared nor paid any cash dividends. The Board of
Directors does not intend to declare any dividends in the foreseeable future,
but instead intends to retain all earnings, if any, for use in our business
operations.

                                       19
<PAGE>


                                     PART II

ITEM 2. CHANGES IN SECURITIES AND USE OF PROCEEDS

RECENT SALES OF UNREGISTERED SECURITIES


On December 19, 2003, the Company issued to Greg Micek, a member of its Board of
Directors 119,637 shares of the Company's common stock in consideration for the
repayment of debt, payment of consulting services and reimbursement of expenses
in the amount of $110,962. Mr. Micek is an accredited individual and the
issuance of the common stock is claimed to be exempt pursuant to Sections 4(2)
and 4(6) of the Securities Act of 1933.


On October 4, 2003, we entered into a private placement offering pursuant to
which we issued 6% convertible debentures in the aggregate face amount of
$200,000 that mature in October 2004 to two accredited investors. Principal and
interest under the debentures are convertible at any time on or prior to
maturity at the option of the holder into shares of our common stock at a
conversion price of $0.64 per share. In connection with this offering we issued
warrants to purchase 160,000 shares of our common stock, at a per share exercise
price of $1.25. The warrants are exercisable from the date of issuance and
expire on October 4, 2005. These debentures and warrants were pursuant to the
exemptions under sections 4(2) and 4(6) of the Securities Act of 1933.

ITEM 3. CONTROLS AND PROCEDURES

In accordance with the Securities and Exchange Act of 1934, as amended, we
carried out an evaluation, under the supervision and with the participation of
management, including our Chief Executive Officer and Chief Financial Officer,
of the effectiveness of our disclosure controls and procedures as of the end of
the period covered by this report. Based on this evaluation, our Chief Executive
Officer and Chief Financial Officer concluded that our disclosure controls and
procedures were effective as of December 31, 2003, to provide reasonable
assurance that information required to be disclosed in our reports filed or
submitted under the Exchange Act is recorded, processed, summarized and reported
within the time periods specified in the Securities and Exchange Commission's
rules and forms. There has been no change in our internal controls over
financial reporting that occurred during the three and six months ended December
31, 2003, that has materially affected, or is reasonably likely to materially
affect, our internal controls over financial reporting.

                                       20


<PAGE>


ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K

a. Exhibits:

EXHIBIT NO. DESCRIPTION

31.1 Certification of Chief Executive Officer pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002.

31.2 Certification of Chief Financial Officer pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002.

32.1 Certification of Chief Executive Officer pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002.

32.2 Certification of Chief Financial Officer pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002.

b. Reports on Form 8-K: None.

                                       21


<PAGE>


                                   SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused
this report to be signed on its behalf by the undersigned, thereunto duly
authorized.

                               IQ BIOMETRIX, INC.
                                  (Registrant)






Date March 31, 2004                     /s/ William Scigliano

                                           ----------------------------
                                           President & CEO


Date March 31, 2004                     /s/ Michael Walsh

                                           ----------------------------
                                           Chief Financial Officer



                                       22